Steven
Basta

The Acid Test

When Steven Basta walked into Phathom Pharmaceuticals in April 2025, he inherited a company with something genuinely rare: a drug that was working. VOQUEZNA (vonoprazan), Phathom's potassium-competitive acid blocker, was outperforming decades-old proton pump inhibitors in clinical trials - 93% erosion healing rates at 8 weeks versus 85% for the competition. The patients were noticing. The gastroenterologists were noticing. What wasn't working was the commercial strategy.

Basta's predecessor had built a broad primary care sales effort. Basta changed direction inside his first quarter. He pivoted to gastroenterologists - the specialists who see the toughest acid-suppression cases, the early adopters, the physicians who would talk to their primary care colleagues once they saw results. Within a year, among Phathom's top 300 GI writers, VOQUEZNA had captured approximately 45% of new-to-brand prescriptions compared to PPIs. Q1 2026 revenue hit $58.3 million - more than double the same period a year earlier.

The pivot was not subtle. Phathom hired nearly 50 new sales representatives and entered Q2 2026 with more than 290 reps trained and deployed specifically for gastroenterology. For a company targeting operating profitability in the second half of 2026, the math is straightforward: dominate the GI specialists first, then let word-of-mouth spread back to primary care.

The Unlikely Engineer

Basta's path into pharmaceutical leadership begins not in a lab but on a drafting table. He studied Biomedical Engineering at Johns Hopkins University - graduating around 1988 - then did what many technically-trained people of that era did: he went to Wall Street. Two years at Dillon, Read & Co. Inc. as an investment banking associate gave him a fluency in capital structures, deal mechanics, and the language that boards speak when the science needs funding.

Then came Kellogg. His MBA from Northwestern's Kellogg Graduate School of Management in the mid-1990s completed the unusual hybrid: deep scientific literacy, operational instincts, and financial fluency. Few CEOs carry all three. He left school and moved directly into operational biopharma - VP of Business Development and CFO at Creative BioMolecules, working on protein therapies and drug-device combinations. Then Executive Director of Product Development at The Immune Response Corporation. Then President and CEO of Gliatech, a medical device company.

By the time he arrived at BioForm Medical in 2002, the pattern was set. Basta was not the scientist in the building - he was the person who could read the science, translate it for investors, and then actually sell the product.

From Faces to Guts: The Strange Resume

Ask Basta's former colleagues to describe his career and the first reaction is usually something like: "Wait, he did all of that?" Between 2002 and today, he has been the chief executive of companies making dermal fillers, anti-gravity treadmills, prescription smartphone apps, nitric oxide nasal sprays, and now a next-generation acid blocker. Each company is in a different therapeutic category. Each had a product that genuinely worked. Each needed someone who could build the commercial engine around it.

BioForm Medical (2002-2010) was the first real showcase. Basta took the company - which made a dermal filler called Radiesse - and built it into the third-largest dermal filler business globally. When Merz, the German aesthetics giant, acquired BioForm, Basta stayed on to run Merz Aesthetics - guiding it to become the third-largest minimally invasive aesthetics firm in the world with operations across 16 countries. It was a master class in post-acquisition integration and global commercial execution.

Then, improbably, came AlterG. From 2011 to 2015 he was CEO of a company that made anti-gravity treadmills for physical rehabilitation - medical-grade devices that let injured athletes and post-surgical patients exercise by reducing gravitational load. Different science. Same commercial challenge: find the right market, build the right team, get the product to the people who need it.

Menlo Therapeutics (2015-2020) brought him back to more traditional pharma. He led the dermatology-focused biotech from 2015 through its transition to VYNE Therapeutics. Then came Mahana Therapeutics, where he oversaw the launch of the first FDA-cleared prescription digital therapeutic for irritable bowel syndrome - a smartphone app, regulated as a Class II medical device, treating the same kind of gut dysfunction that now consumes much of his attention at Phathom.

Before Phathom, there was SaNOtize - a Vancouver-based biotech using nitric oxide to fight infections. Basta became CEO in September 2023 and helped oversee the launch of novel topical anti-infective products in the United States. He stayed until May 2025, overlapping with his start at Phathom by a matter of weeks.

VOQUEZNA and the P-CAB Opportunity

Vonoprazan - the molecule behind VOQUEZNA - is a potassium-competitive acid blocker, or P-CAB. Unlike proton pump inhibitors, which require an acid environment to activate and take days to reach full effect, P-CABs work faster and maintain more consistent acid suppression. In Phathom's Phase III erosive esophagitis trial, approximately 93% of patients healed their erosions by 8 weeks - compared to 85% for the leading PPI in competitor data. For H. pylori eradication, vonoprazan-based dual and triple therapy regimens are rewriting the treatment algorithm.

Basta's commercial bet is built around category creation. There is now a second P-CAB entering the US market (Tegoprazan, developed by a competitor). Rather than treating this as a threat, Basta frames it as useful - two companies talking about P-CABs will expand category awareness faster than one. His position on the competitive dynamic is direct: the clinical data for VOQUEZNA is superior, and no gastroenterologist is going to switch a stable patient without a compelling reason.

"There's just no compelling reason for anyone to switch a patient from VOQUEZNA to Tegoprazan," he told analysts in April 2026. "The data doesn't suggest that the patient is going to do better."

Phathom is also expanding the VOQUEZNA program beyond GERD and H. pylori. In 2025, the company dosed its first patient in a Phase 2 study of vonoprazan in eosinophilic esophagitis (EoE) - a chronic, immune-mediated condition that causes difficulty swallowing and has few approved treatments. If that data reads out positively, the addressable market expands significantly.

The Long Game

Basta's thesis at Phathom is sequential. Gastroenterologists first - not because they are the only prescribers, but because they are the highest-value early adopters and the physicians most likely to generate durable word-of-mouth back to primary care. By April 2026, 1.35 million VOQUEZNA prescriptions had been filled. The company has a clear milestone: operating profitability in the second half of 2026, with annual GI revenue eventually reaching $1 billion.

The second billion - primary care - is a longer-term prize. Basta's model relies on patient advocacy: people who feel dramatically better on VOQUEZNA will tell their primary care physicians, who will write the script. "Those same patients telling gastroenterologists how much better they feel will go back to their primary care physician next year," he has said. The product markets itself to the PCPs through the patients.

Meanwhile, he serves on the boards of DermBiont, Inc. - a company using the skin microbiome to develop new dermatology treatments - and VYNE Therapeutics, the former Menlo company he led to its transformation. For someone who pivots freely between categories, the board seats reveal a consistent interest: the intersection of biology, commercial strategy, and patient outcomes.

His employees rate him at 97 out of 100 - placing him in the top 5% of CEOs at similarly-sized companies. That kind of score doesn't come from quarterly revenue beats alone. It comes from being the kind of leader who knows the science, respects the people building the company around it, and can articulate a destination clearly enough that the organization actually moves toward it.

The stomach is not glamorous. But Basta has never been drawn to the glamorous markets. He's been drawn to the ones where the product is genuinely better and the commercial story just needs to be told correctly. That instinct has worked across six categories and more than two decades. The current bet - vonoprazan as a category-defining acid blocker - is the biggest stage he's played on yet.